Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.

Publication ,  Journal Article
Costello, BA; Bhavsar, NA; Zakharia, Y; Pal, SK; Vaishampayan, U; Jim, H; Fishman, MN; Molina, AM; Kyriakopoulos, CE; Tsao, C-K; Appleman, LJ ...
Published in: Clin Genitourin Cancer
February 2022

INTRODUCTION: The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC). METHODS AND MATERIALS: Patients with mRCC and no prior systemic therapy were enrolled at academic and community sites. End of study data collection was in March 2019. Outcomes included overall survival (OS). A survey of treating physicians assessed reasons for treatment initiations and discontinuations. RESULTS: Overall, 376 patients with mRCC initiated first-line therapy; 171 (45.5%) received pazopanib, 75 (19.9%) sunitinib, and 74 (19.7%) participated in a clinical trial. Median (95% confidence interval) OS was longest in the clinical trial group (50.3 [35.8-not reached] months) versus pazopanib (39.0 [29.7-50.9] months) and sunitinib 26.2 [19.9-61.5] months). Non-clear cell RCC (21.5% of patients) was associated with worse median OS than clear cell RCC (18.0 vs. 47.3 months). Differences in baseline characteristics, treatment starting dose, and relative dose exposure among treatment groups suggest selection bias. Survey results revealed a de-emphasis on quality of life, toxicity, and patient preference compared with efficacy in treatment selection. CONCLUSION: The MaRCC Registry gives insights into real-world first-line treatment selection, outcomes, and physician rationale regarding initial treatment selection prior to the immunotherapy era. Differences in outcomes between clinical trial and off-study patients reflect the difficulty in translating trial results to real-world patients, and emphasize the need to broaden clinical trial eligibility. Physician emphasis on efficacy over quality of life and toxicity suggests more data and education are needed regarding these endpoints.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

February 2022

Volume

20

Issue

1

Start / End Page

1 / 10

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sunitinib
  • Retrospective Studies
  • Registries
  • Quality of Life
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Male
  • Kidney Neoplasms
  • Indazoles
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Costello, B. A., Bhavsar, N. A., Zakharia, Y., Pal, S. K., Vaishampayan, U., Jim, H., … Harrison, M. R. (2022). A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer, 20(1), 1–10. https://doi.org/10.1016/j.clgc.2021.07.002
Costello, Brian A., Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka Vaishampayan, Heather Jim, Mayer N. Fishman, et al. “A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.Clin Genitourin Cancer 20, no. 1 (February 2022): 1–10. https://doi.org/10.1016/j.clgc.2021.07.002.
Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, et al. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 Feb;20(1):1–10.
Costello, Brian A., et al. “A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.Clin Genitourin Cancer, vol. 20, no. 1, Feb. 2022, pp. 1–10. Pubmed, doi:10.1016/j.clgc.2021.07.002.
Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao C-K, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 Feb;20(1):1–10.
Journal cover image

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

February 2022

Volume

20

Issue

1

Start / End Page

1 / 10

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sunitinib
  • Retrospective Studies
  • Registries
  • Quality of Life
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Male
  • Kidney Neoplasms
  • Indazoles